Build Your Comparison

Side-by-side financial analysis
GOSS logo
GOSS
AVXL logo
AVXL
KO logo
KO
Try popular comparisons:

Stock Comparison

GOSS vs AVXL vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
GOSS
Gossamer Bio, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$38M
5Y Perf.-98.8%
AVXL
Anavex Life Sciences Corp.

Biotechnology

HealthcareNASDAQ • US
Market Cap$232M
5Y Perf.-49.2%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%

GOSS vs AVXL vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
GOSS logoGOSS
AVXL logoAVXL
KO logoKO
IndustryBiotechnologyBiotechnologyBeverages - Non-Alcoholic
Market Cap$38M$232M$355.61B
Revenue (TTM)$56M$49.28B
Net Income (TTM)$-180M$-40M$13.70B
Gross Margin99.6%61.7%
Operating Margin-321.9%29.3%
Forward P/E25.3x
Total Debt$202M$0.00$45.49B
Cash & Equiv.$38M$103M$10.27B

GOSS vs AVXL vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

GOSS
AVXL
KO
StockJun 20Jun 26Return
Gossamer Bio, Inc. (GOSS)1001.2-98.8%
Anavex Life Science… (AVXL)10050.8-49.2%
The Coca-Cola Compa… (KO)100184.9+84.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: GOSS vs AVXL vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: KO leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Anavex Life Sciences Corp. is the stronger pick specifically for capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
🥇KO emerged as the overall leader. Track its performance:
GOSS
Gossamer Bio, Inc.
The Secondary Option

GOSS plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
AVXL
Anavex Life Sciences Corp.
The Income Pick

AVXL is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • Dividend streak 0 yrs, beta 1.77
  • Lower volatility, beta 1.77, current ratio 11.60x
  • Beta 1.77, current ratio 11.60x
Best for: income & stability and sleep-well-at-night
KO
The Coca-Cola Company
The Growth Play

KO carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 1.9%, EPS growth 23.6%, 3Y rev CAGR 3.7%
  • 121.1% 10Y total return vs AVXL's -38.3%
  • 1.9% revenue growth vs GOSS's -57.7%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthKO logoKO1.9% revenue growth vs GOSS's -57.7%
Quality / MarginsKO logoKO27.8% margin vs GOSS's -324.8%
Stability / SafetyAVXL logoAVXLBeta 1.77 vs GOSS's 2.45
DividendsKO logoKO2.5% yield; 56-year raise streak; the other 2 pay no meaningful dividend
Momentum (1Y)KO logoKO+17.2% vs GOSS's -87.3%
Efficiency (ROA)KO logoKO13.1% ROA vs GOSS's -96.1%, ROIC 15.8% vs -107.5%

GOSS vs AVXL vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

GOSSGossamer Bio, Inc.
FY 2025
License and Service
0.0%$0
AVXLAnavex Life Sciences Corp.

Segment breakdown not available.

KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

GOSS vs AVXL vs KO — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLKOLAGGINGGOSS

Income & Cash Flow (Last 12 Months)

KO leads this category, winning 3 of 6 comparable metrics.

KO is the larger business by revenue, generating $49.3B annually — 887.4x GOSS's $56M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to GOSS's -3.2%. On growth, GOSS holds the edge at +71.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricGOSS logoGOSSGossamer Bio, Inc.AVXL logoAVXLAnavex Life Scien…KO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$56M$49.3B
EBITDAEarnings before interest/tax-$178M-$39M$15.5B
Net IncomeAfter-tax profit-$180M-$40M$13.7B
Free Cash FlowCash after capex-$170M-$34M$12.6B
Gross MarginGross profit ÷ Revenue+99.6%+61.7%
Operating MarginEBIT ÷ Revenue-3.2%+29.3%
Net MarginNet income ÷ Revenue-3.2%+27.8%
FCF MarginFCF ÷ Revenue-3.1%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+71.5%+12.1%
EPS Growth (YoY)Latest quarter vs prior year-25.0%+54.4%+18.2%
KO leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

AVXL leads this category, winning 2 of 3 comparable metrics.
MetricGOSS logoGOSSGossamer Bio, Inc.AVXL logoAVXLAnavex Life Scien…KO logoKOThe Coca-Cola Com…
Market CapShares × price$38M$232M$355.6B
Enterprise ValueMkt cap + debt − cash$202M$129M$390.8B
Trailing P/EPrice ÷ TTM EPS-0.22x-4.63x27.18x
Forward P/EPrice ÷ next-FY EPS est.25.27x
PEG RatioP/E ÷ EPS growth rate2.43x
EV / EBITDAEnterprise value multiple26.39x
Price / SalesMarket cap ÷ Revenue0.78x7.42x
Price / BookPrice ÷ Book value/share2.25x10.40x
Price / FCFMarket cap ÷ FCF67.15x
AVXL leads this category, winning 2 of 3 comparable metrics.

Profitability & Efficiency

KO leads this category, winning 6 of 8 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-39 for AVXL. On the Piotroski fundamental quality scale (0–9), KO scores 7/9 vs GOSS's 0/9, reflecting strong financial health.

MetricGOSS logoGOSSGossamer Bio, Inc.AVXL logoAVXLAnavex Life Scien…KO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity-38.8%+41.1%
ROA (TTM)Return on assets-96.1%-35.0%+13.1%
ROICReturn on invested capital-107.5%+15.8%
ROCEReturn on capital employed-86.1%-47.8%+17.3%
Piotroski ScoreFundamental quality 0–9027
Debt / EquityFinancial leverage1.33x
Net DebtTotal debt minus cash$164M-$103M$35.2B
Cash & Equiv.Liquid assets$38M$103M$10.3B
Total DebtShort + long-term debt$202M$0$45.5B
Interest CoverageEBIT ÷ Interest expense-15.50x10.70x
KO leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

KO leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in KO five years ago would be worth $16,560 today (with dividends reinvested), compared to $184 for GOSS. Over the past 12 months, KO leads with a +17.2% total return vs GOSS's -87.3%. The 3-year compound annual growth rate (CAGR) favors KO at 13.7% vs GOSS's -48.0% — a key indicator of consistent wealth creation.

MetricGOSS logoGOSSGossamer Bio, Inc.AVXL logoAVXLAnavex Life Scien…KO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-94.4%-32.1%+20.3%
1-Year ReturnPast 12 months-87.3%-69.6%+17.2%
3-Year ReturnCumulative with dividends-85.9%-71.1%+47.0%
5-Year ReturnCumulative with dividends-98.2%-88.1%+65.6%
10-Year ReturnCumulative with dividends-99.1%-38.3%+121.1%
CAGR (3Y)Annualised 3-year return-48.0%-33.9%+13.7%
KO leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than GOSS's 2.45 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs GOSS's 4.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricGOSS logoGOSSGossamer Bio, Inc.AVXL logoAVXLAnavex Life Scien…KO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5002.45x1.77x-0.20x
52-Week HighHighest price in past year$3.87$13.99$84.04
52-Week LowLowest price in past year$0.14$2.41$65.35
% of 52W HighCurrent price vs 52-week peak+4.2%+17.9%+98.3%
RSI (14)Momentum oscillator 0–10034.136.860.6
Avg Volume (50D)Average daily shares traded10.7M1.0M12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

KO leads this category, winning 1 of 1 comparable metric.

Analyst consensus: GOSS as "Buy", AVXL as "Buy", KO as "Buy". Consensus price targets imply 373.6% upside for GOSS (target: $1) vs 4.2% for KO (target: $86). KO is the only dividend payer here at 2.46% yield — a key consideration for income-focused portfolios.

MetricGOSS logoGOSSGossamer Bio, Inc.AVXL logoAVXLAnavex Life Scien…KO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyBuyBuy
Price TargetConsensus 12-month target$0.77$11.00$86.13
# AnalystsCovering analysts171348
Dividend YieldAnnual dividend ÷ price+2.5%
Dividend StreakConsecutive years of raises056
Dividend / ShareAnnual DPS$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+0.2%
KO leads this category, winning 1 of 1 comparable metric.
Key Takeaway

KO leads in 5 of 6 categories (Income & Cash Flow, Profitability & Efficiency). AVXL leads in 1 (Valuation Metrics).

Best OverallThe Coca-Cola Company (KO)Leads 5 of 6 categories
Loading custom metrics...

GOSS vs AVXL vs KO: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is GOSS or AVXL or KO a better buy right now?

For growth investors, The Coca-Cola Company (KO) is the stronger pick with 1.

9% revenue growth year-over-year, versus -57. 7% for Gossamer Bio, Inc. (GOSS). The Coca-Cola Company (KO) offers the better valuation at 27. 2x trailing P/E (25. 3x forward), making it the more compelling value choice. Analysts rate Gossamer Bio, Inc. (GOSS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — GOSS or AVXL or KO?

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

6%, compared to -98. 2% for Gossamer Bio, Inc. (GOSS). Over 10 years, the gap is even starker: KO returned +121. 1% versus GOSS's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — GOSS or AVXL or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Gossamer Bio, Inc. 's 2. 45β — meaning GOSS is approximately -1322% more volatile than KO relative to the S&P 500.

04

Which is growing faster — GOSS or AVXL or KO?

By revenue growth (latest reported year), The Coca-Cola Company (KO) is pulling ahead at 1.

9% versus -57. 7% for Gossamer Bio, Inc. (GOSS). On earnings-per-share growth, the picture is similar: The Coca-Cola Company grew EPS 23. 6% year-over-year, compared to -200. 0% for Gossamer Bio, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — GOSS or AVXL or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -351. 5% for Gossamer Bio, Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -336. 8% for GOSS. At the gross margin level — before operating expenses — GOSS leads at 97. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is GOSS or AVXL or KO more undervalued right now?

Analyst consensus price targets imply the most upside for GOSS: 373.

6% to $0. 77.

07

Which pays a better dividend — GOSS or AVXL or KO?

In this comparison, KO (2.

5% yield) pays a dividend. GOSS, AVXL do not pay a meaningful dividend and should not be held primarily for income.

08

Is GOSS or AVXL or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Gossamer Bio, Inc. (GOSS) carries a higher beta of 2. 45 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, GOSS: -99. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between GOSS and AVXL and KO?

These companies operate in different sectors (GOSS (Healthcare) and AVXL (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

KO pays a dividend while GOSS, AVXL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.